BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Trastuzumab pamirtecan readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Trastuzumab pamirtecan\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05150691-2448@assetmemo.bio
DTSTAMP:20261121T005018Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Trastuzumab pamirtecan: Phase 1/2 readout est. (NCT05150691)
DESCRIPTION:Trastuzumab pamirtecan\, phase 1/2.\nStudy: A Phase 1/2a Study 
 of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors\nEstimated primary c
 ompletion: August 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/trastuzumab-pamirtecan#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05150691
URL:https://assetmemo.bio/drug/trastuzumab-pamirtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06265428-2448@assetmemo.bio
DTSTAMP:20261121T005018Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab pamirtecan: Phase 3 readout est. (NCT06265428)
DESCRIPTION:Trastuzumab pamirtecan\, phase 3\, HER2-Positive Breast Cancer.
 \nStudy: A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer\n
 Estimated primary completion: December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/trastuzumab-pamirtecan#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06265428
URL:https://assetmemo.bio/drug/trastuzumab-pamirtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06340568-2448@assetmemo.bio
DTSTAMP:20261121T005018Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Trastuzumab pamirtecan: Phase 3 readout est. (NCT06340568)
DESCRIPTION:Trastuzumab pamirtecan\, phase 3\, Endometrial Cancer.\nStudy: 
 A Clinical Study of the Anti-cancer Effects of an Investigational Therapy 
 or Chemotherapy in Patients With Recurring Uterine Cancer\nEstimated prima
 ry completion: March 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/trastuzumab-pamirtecan#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06340568
URL:https://assetmemo.bio/drug/trastuzumab-pamirtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06827236-2448@assetmemo.bio
DTSTAMP:20261121T005018Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Trastuzumab pamirtecan: Phase 1/2 readout est. (NCT06827236)
DESCRIPTION:Trastuzumab pamirtecan\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: A Clinical Study to Find the Optimal Dose of an Investig
 ational Treatment Called BNT323 When Used in Combination With Another Inve
 stigational Treatment\, BNT327\, and to Test if That Combination Treatment
  is Safe and Beneficial for Patients With Advanced Breast Cancer\nEstimate
 d primary completion: August 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/trastuzumab-pamirtecan#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06827236
URL:https://assetmemo.bio/drug/trastuzumab-pamirtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
